Full Text
Budget Impact Analysis of Using Pazopanib-Everolimus in First and Second Line of Treatment, In Patients with Metastatic Renal Cell Carcinoma

Abstract

Authors

ME Romero Prada S Celis G Acero LM Huerfano

Back to Volume 19, Issue 7
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×